Recent Updates
Recently added Catalysts

Experimental Peritoneal Dialysis

Phase 3

End Stage Renal Disease | Small molecule | Nephrology |Baxter International Inc.|Last Updated: Mar 3, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment120
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00214721A Study to Evaluate the Efficacy and Safety of an Experimental Solution for Peritoneal DialysisPHASE3 COMPLETED 120Feb 1, 2005Jul 1, 2006Mar 3, 20251 Canada
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
Experimental Peritoneal Dialysis SolutionDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Patients who have given written informed consent after the nature of the study has been explained. * Patients who are at least 18 years of age. * Patients who have been treated with CAPD using specific solutions for at least 60 days before the baseline visit. Exclusion Criter...

Countries:Canada
Unlock Eligibility Criteria